Revolution Medicines’ daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics’ Filspari receives FDA approval as the first-ever treatment for focal segmental glomerulosclerosis, IDEAYA Biosciences and Servier’s darovasertib combination meets its Phase 2/3 primary endpoint in metastatic uveal melanoma, and Spyre Therapeutics reports best-in-class potential for SPY001 in the Phase 2 SKYLINE trial for ulcerative colitis — the most significant clinical trial results 17 April 2026 has to offer from across the pipeline.
This week delivered an exceptional cluster of readouts across oncology, rare kidney disease, and gastroenterology, making it one of the most consequential single weeks for clinical data so far in 2026. The pancreatic cancer result from Revolution Medicines is being described as unprecedented by leading investigators, a disease area that has long resisted meaningful progress beyond cytotoxic chemotherapy. Here, Life Science Daily News brings you the most significant clinical trial results 17 April 2026.
Revolution Medicines’ Daraxonrasib Nearly Doubles Overall Survival in Pivotal Phase 3 Pancreatic Cancer Trial
Revolution Medicines announced on 13 April 2026 positive topline results from the global, randomised, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib as a monotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results have been described by leading investigators as unprecedented for a Phase 3 trial in this indication.
The co-primary endpoints of the RASolute 302 trial were progression-free survival and overall survival in patients with RAS G12 mutations specifically. Both were met with statistically significant and clinically meaningful results. As a key secondary endpoint, daraxonrasib also delivered a median overall survival of 13.2 months in the overall intent-to-treat population, which included patients across all RAS variants as well as those without an identified RAS mutation, compared with 6.7 months for standard-of-care cytotoxic chemotherapy, a gain of 6.5 months corresponding to a hazard ratio of 0.40 (p<0.0001). Based on the first interim analysis, Revolution Medicines has declared all primary and secondary endpoint results final. The drug demonstrated a manageable safety profile with no new safety signals; rash, a known class effect, was the most commonly reported adverse event and was generally treatable with dose modification or antibiotic therapy.
RASolute 302 (ClinicalTrials.gov identifier: NCT06625320) was a randomised, controlled Phase 3 trial comparing daraxonrasib 300 mg taken orally once daily against investigator’s choice of intravenous chemotherapy in patients with previously treated metastatic PDAC. The trial enrolled approximately 501 patients with tumours harbouring a range of RAS G12 variants, including G12D, G12V, and G12R, as well as patients without an identified RAS mutation. Daraxonrasib is an oral RAS(ON) multi-selective, non-covalent inhibitor targeting the activated form of RAS, a protein long considered undruggable. Pancreatic ductal adenocarcinoma is one of the most lethal of all common cancers, with a five-year survival rate of approximately 13% across all stages and significantly lower for metastatic disease. RAS mutations are estimated to drive more than 90% of PDAC cases.
Revolution Medicines has stated it intends to submit a New Drug Application to the FDA under a Commissioner’s National Priority Voucher, a designation that enables expedited review within one to two months. Full data from RASolute 302 will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. A first-line Phase 3 trial (RASolute 303) is already underway, and a Phase 3 study in non-small cell lung cancer is also in progress.
Travere Therapeutics’ Filspari Receives FDA Approval as First-Ever Treatment for FSGS
Travere Therapeutics announced on 13 April 2026 that the FDA has approved Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. Filspari is now the first and only medicine approved by the FDA for the treatment of FSGS, a rare, progressive kidney disorder that is a leading cause of kidney failure and has previously had no targeted approved therapies.
The approval is supported by results from the Phase 3 DUPLEX study, the largest head-to-head interventional study ever conducted in FSGS, which enrolled 371 patients aged eight to 75 years with biopsy-proven or genetic FSGS across a global, randomised, double-blind, active-controlled trial. Patients were randomised 1:1 to receive either Filspari or irbesartan, titrated to maximum dose. In the overall study population, patients treated with Filspari experienced a statistically significant 46% reduction in proteinuria from baseline to week 108 compared with 30% for irbesartan (nominal p-value 0.0299). In the approved subgroup without nephrotic syndrome, results were stronger still, with a 48% reduction compared with 27% for irbesartan (nominal p-value 0.0075). Two-year results from the DUPLEX study were published in the New England Journal of Medicine.
Filspari works through a dual mechanism, targeting both endothelin A receptors and angiotensin II receptors, two pathways implicated in the inflammation and progressive scarring that characterise FSGS. The drug is already the most commonly prescribed FDA-approved treatment for IgA nephropathy, and this new indication expands its addressable population to an estimated 100,000 patients in the United States with FSGS and IgAN combined. Travere confirmed that Filspari is immediately available for nephrologists to prescribe for FSGS patients. The approval also extends the indication to children as young as eight years old, filling a significant gap in paediatric nephrology where management has historically relied on off-label immunosuppressants, including long-term corticosteroids and calcineurin inhibitors, with significant toxicity profiles and variable efficacy in steroid-resistant cases.
IDEAYA Biosciences and Servier’s Darovasertib Combination Meets Phase 2/3 Primary Endpoint in Metastatic Uveal Melanoma
IDEAYA Biosciences and Servier announced on 13 April 2026 positive topline results from the Phase 2/3 registrational trial OptimUM-02, evaluating darovasertib in combination with crizotinib as a first-line treatment for patients with HLA-A*02:01-negative metastatic uveal melanoma (mUM), a rare and aggressive form of ocular cancer with no currently approved therapies in this patient subgroup.
The darovasertib combination met the trial’s primary endpoint, demonstrating a statistically significant improvement in median progression-free survival as assessed by blinded independent central review: 6.9 months versus 3.1 months for investigator’s choice of therapy (hazard ratio 0.42; 95% CI: 0.30, 0.59; p<0.0001). The objective response rate, a key secondary endpoint, was 37.1% for the darovasertib combination versus 5.8% for the comparator arm (p<0.0001), including five complete responses in the darovasertib arm. An early trend in overall survival improvement was also observed. The drug combination was well tolerated, with a manageable safety profile consistent with previously reported adverse events.
OptimUM-02 enrolled 313 patients in its Phase 2b/3 portion, randomising 210 patients to the darovasertib combination and 103 patients to investigator’s choice of therapy, which reflected real-world clinical practice and comprised predominantly ipilimumab plus nivolumab (76%) and pembrolizumab (24%). Uveal melanoma is a rare, aggressive form of ocular cancer in which approximately 95% of patients carry activating mutations in GNAQ/GNA11 GTPase proteins that drive downstream protein kinase C signalling and tumour growth. There are currently no approved therapies for metastatic uveal melanoma in the HLA-A*02:01-negative population, the majority of metastatic uveal melanoma patients who are not eligible for the only currently approved treatment, tebentafusp. IDEAYA and Servier plan to submit a New Drug Application to the FDA in the second half of 2026 to support accelerated approval.
Spyre Therapeutics’ SPY001 Demonstrates Best-in-Class Potential in Phase 2 SKYLINE Trial for Ulcerative Colitis
Spyre Therapeutics announced on 13 April 2026 positive topline induction data from Part A of the Phase 2 SKYLINE platform trial evaluating SPY001, an extended half-life anti-α4β7 monoclonal antibody, in 43 patients with moderate-to-severely active ulcerative colitis (UC).
SPY001 met the trial’s primary endpoint with a statistically significant 9.2-point reduction from baseline in Robarts Histopathology Index score at week 12 (p<0.0001), a validated histological measure of UC disease activity. Secondary endpoints were also encouraging: clinical remission, as measured by modified Mayo Score, was achieved in 40% of patients, and endoscopic improvement was observed in 51%, outcomes that compare favourably against existing approved α4β7 therapies including Takeda’s vedolizumab (Entyvio), the current standard in gut-selective treatment. The modified Mayo Score also improved by 3.7 points. SPY001 was well tolerated, with a safety profile consistent with the α4β7 class; six participants experienced treatment-emergent adverse events, the most common being back pain (n=2), and one serious adverse event was deemed unrelated to the drug.
SPY001 targets the same intestinal integrin epitope as vedolizumab but is engineered with an approximately three-fold extended half-life, supporting potential quarterly or biannual subcutaneous maintenance dosing via autoinjector, a significant convenience advantage over vedolizumab’s current every-two-week subcutaneous regimen. Analysts have noted the 40% clinical remission rate comfortably exceeds the 20 to 25% range typically associated with class-aligned performance, and have positioned SPY001 as a credible backbone for the combination regimens planned in Part B of SKYLINE, which will assess SPY001 alongside SPY002 (anti-TL1A) and SPY003 (anti-IL-23) both as monotherapies and in pairwise combinations. Proof-of-concept data from the SPY002 and SPY003 monotherapy arms of Part A are expected in mid-2026 and Q3 2026 respectively, with Part B combination data on track for 2027.
Looking Ahead
This week’s clinical trial results 17 April 2026 mark a genuinely remarkable period for the global pharmaceutical pipeline, spanning some of the most challenging disease areas in medicine. Daraxonrasib’s Phase 3 result in pancreatic cancer represents a potential generational advance in an indication that has resisted progress for decades. Filspari’s approval as the first-ever FSGS treatment gives thousands of patients with a devastating kidney disease a targeted option for the first time. Darovasertib’s Phase 2/3 success in uveal melanoma extends precision oncology into another rare tumour type with no prior approved therapy. And SPY001’s SKYLINE data raise the prospect of a new, more convenient backbone for IBD treatment that could challenge an established blockbuster. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 17 April 2026 that matter most across the global life sciences pipeline.
This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently
